Multiple studies have demonstrated that one of the most common mechanisms of cancer cell resistance to CDK4/6 inhibitors is loss of function of Rb (mutation, hyperphosphorylation or deletion) (Dean et al., 2012; Malorni et al., 2016; Vijayaraghavan et al., 2017). This evidence concerns the gene RB1 and cancer.